Desmitis of the collateral ligament of the distal interpahlangeal joint in horses: regenerative medicine techniques and outcome
[um_loggedin show_lock=yes]Authors: Pablo Espinosa Mur, Mathieu Spriet, Hannah T. Jarvis, Rodrigo Roca, Dori L. Borjesson, Larry D. Galuppo
Affiliations: University of California. School of Veterinary Medicine, Davis.
Introduction: Desmitis of the collateral ligaments of the distal interphalangeal joint (CLDIPJ) is a common condition in horses that causes distal limb lameness in horses. This condition has beem more readily identified since the introduction of magnetic resonance imaging (MRI) in the equine field. Several treatment options are available today. Regenerative medicine treatment options include mesenchymal stem cells (MSCs), bone marrow concentrate aspirate (BMAC), platelet rich plasma (PRP) and autologous conditioned serum (ACS). This report summarizes the regenerative medicine treatment, injection techniques, complications and outcome in horses treated with this condition.
Hypothesis/Objectives: We hypothesized that horses affected with CLDIPJ desmitis and treated with regenerative medicine techniques would have similar outcome to previous reports.
Materials and Methods: Signalment, lameness duration, blocking pattern, MRI lesion grade (mild, moderate or severe), limb, affected side (medial vs lateral) and outcome of horses presenting with desmitis of the CLDIPJ and treated with MSCs, BMAC, PRP or ACS between 2006 and 2017 were recorded.
Results: 21 Horses met the inclusion criteria (median age = 9 years; 4-23 range). Seven horses were used for show jumping, five for dressage, four for western performance, two for trail riding and another two for endurance racing. Lameness grade ranged between 2 and 4 out of five and the score more commonly assigned was 3/5 (17/21 horses). MSCs were used in ten cases, BMAC was used in two cases, ACS was used in seven cases and PRP in five cases. The degree of lameness improved in 17/21 horses and lameness completely resolved in 11/21 cases.
Conclusions: In the current report in 57% (12/21) of the horses treated with regenerative medicine techniques showed resolution of lameness and returned to previous level of activity. Our results are comparable to previous report where a combination of other treatments were performed. Future case control studies are required to further determine the effect of regenerative medicine therapies in the treatment of desmitis of the CLDIPJ.
Acknowledgements, Funding, and Conflicts of Interest: The authors gratefully acknowledge Soli Redfield (VMTH, UC Davis. CA) for her support.[/um_loggedin]